Musa F - Search Results

1

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.

Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A. Musa F, et al. Gynecol Oncol. 2017 Feb;144(2):279-284. doi: 10.1016/j.ygyno.2016.11.043. Epub 2016 Dec 5. Gynecol Oncol. 2017. PMID: 27931751 Clinical Trial.

2

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR. Chi DS, et al. Among authors: musa f. Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13. Gynecol Oncol. 2012. PMID: 21917306

3

A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.

Musa F, Blank S, Muggia F. Musa F, et al. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):215-24. doi: 10.1517/17425255.2013.758249. Expert Opin Drug Metab Toxicol. 2013. PMID: 23320990 Review.

4

Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.

Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ. Korets SB, et al. Among authors: musa f. Gynecol Oncol. 2014 Feb;132(2):468-73. doi: 10.1016/j.ygyno.2013.11.027. Epub 2013 Dec 4. Gynecol Oncol. 2014. PMID: 24316308 Free PMC article.

5

Cross-Sectional Study of the Impact of a Natural Disaster on the Delivery of Gynecologic Oncology Care.

David-West G, Musa F, Frey MK, Boyd L, Pothuri B, Curtin JP, Blank SV. David-West G, et al. Among authors: musa f. Disaster Med Public Health Prep. 2015 Dec;9(6):605-8. doi: 10.1017/dmp.2015.83. Epub 2015 Jul 9. Disaster Med Public Health Prep. 2015. PMID: 26155945

6

Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?

Frey MK, Moss HA, Musa F, Rolnitzky L, David-West G, Chern JY, Boyd LR, Curtin JP. Frey MK, et al. Among authors: musa f. Cancer. 2016 Mar 15;122(6):859-67. doi: 10.1002/cncr.29859. Epub 2016 Jan 27. Cancer. 2016. PMID: 26938270 Free article.

7

Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.

Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ. Musa F, et al. Mol Cancer Ther. 2016 Jul;15(7):1557-67. doi: 10.1158/1535-7163.MCT-15-0926. Epub 2016 May 16. Mol Cancer Ther. 2016. PMID: 27196780 Free PMC article.

8

Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin.

Kudlowitz D, Velastegui A, Musa F, Muggia F. Kudlowitz D, et al. Among authors: musa f. Cancer Chemother Pharmacol. 2018 May;81(5):847-851. doi: 10.1007/s00280-018-3559-y. Epub 2018 Mar 7. Cancer Chemother Pharmacol. 2018. PMID: 29516152

9

Neoadjuvant chemotherapy in patients with advanced endometrial cancer.

Khouri OR, Frey MK, Musa F, Muggia F, Lee J, Boyd L, Curtin JP, Pothuri B. Khouri OR, et al. Among authors: musa f. Cancer Chemother Pharmacol. 2019 Aug;84(2):281-285. doi: 10.1007/s00280-019-03838-x. Epub 2019 Apr 12. Cancer Chemother Pharmacol. 2019. PMID: 30980132

10

Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.

Musa FB, Brouwer E, Ting J, Schwartz NRM, Surinach A, Bloudek L, Ramsey SD. Musa FB, et al. Gynecol Oncol. 2022 Mar;164(3):645-650. doi: 10.1016/j.ygyno.2021.12.028. Epub 2022 Jan 12. Gynecol Oncol. 2022. PMID: 35031189

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

74 results

Search Page